As the direct-to-patient (DTP) model gains traction across the pharmaceutical landscape, companies are grappling with one ...
In today's Pharma Pulse, the FDA flags misleading promotional claims from ImmunityBio regarding its cancer therapy and ...
The FDA's March 7, 2026 final rule mandating a uniform 12-digit National Drug Code—effective March 7, 2033, with a three-year ...
Patient support programs continue to play a role in how pharmaceutical manufacturers address access and adherence challenges, ...
In today’s Pharma Pulse, industry leaders warn of serialization security issues and pharma companies brace for the 2033 NDC ...
Pharmaceutical companies are increasingly shifting their focus from healthcare providers to patients as the primary customer ...
Regulatory regimes such as the EU FMD and U.S. DSCSA drive serialization to strengthen visibility and oversight, but these ...
MedImpact has announced the launch of GLP-1 Benefit 360 and GLP-1 Direct Fund, aimed at addressing inefficiencies in the drug ...
Shifting cost dynamics and infrastructure capabilities are prompting manufacturers to reassess traditional distribution channels. In the final installment of his three-part interview series, Jay ...
Jordan Armstrong outlines how adaptable DTP programs can reduce barriers and accelerate patient access to therapy. As ...
As global temperatures continue to rise and weather patterns grow more volatile, the pharmaceutical industry faces a mounting ...
From KPI clarity to right-sized staffing, Kimberly Howard explains how to measure true FRM impact and build flexible models ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results